+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and effectiveness of the whole-cell pneumococcal wSp vaccine in preventing nasopharyngeal colonization by Streptococcus pneumoniae bacteria in healthy young children aged approximately 6 to 7 months who have already received routine PCV15 or PCV20 vaccinations. The study aims to determine whether the wSp vaccine reduces bacterial colonization in the nose and safely stimulates the immune system to produce protective antibodies. Participants will receive two intramuscular injections of either the wSp vaccine or a saline placebo at about 7 and 9 months of age. The wSp vaccine contains 1 mg of total protein per 0.5 mL dose and is given preferably in the left thigh for the first dose and the right thigh for the second. The placebo group will receive saline injections following the same schedule. The study is randomized and blinded to compare outcomes between these two groups. During the study, children will have blood samples taken at 6 andor 12 months to measure immune responses, and nasal swabs will be collected at multiple time points and during respiratory infections from 6 to 24 months of age. Researchers will monitor occurrences of ear infections, respiratory illnesses, and other pneumococcal-related infections to assess the vaccines impact. The main outcome measured is the presence of Streptococcus pneumoniae in the nasopharynx at various times after vaccination and during infection episodes.

Age: 5Months - 7MonthsAll GendersPhase 2
7 locations